StockNews.AI
ATOS
StockNews.AI
152 days

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

1. Atossa scheduled a Q4 2024 financial results call on March 25. 2. Company focuses on innovative breast cancer therapies, including (Z)-endoxifen. 3. The call will detail corporate progress and clinical developments. 4. Investors can access the call via phone or webcast.

4m saved
Insight
Article

FAQ

Why Bullish?

Atossa’s focus on breast cancer innovation suggests potential market interest and future earnings growth. Past announcements of clinical trial successes have led to favorable stock movements.

How important is it?

The announcement reflects Atossa's ongoing commitment to breast cancer treatment, likely affecting investor sentiment and interest. Its lead product's progress can directly impact stock price.

Why Short Term?

The upcoming conference call will provide immediate insights into financial health and strategic direction. Timing aligns with quarterly reporting, which tends to influence stock price in the near term.

Related Companies

PTCTREGNAVEO
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time March 20, 2025 09:13 ET  | Source: Atossa Therapeutics, Inc. SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Atossa Therapeutics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at www.atossatherapeutics.com. About Atossa Therapeutics        Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including metastatic, neoadjuvant, adjuvant, and prevention settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.  ContactMichael Parks, VP Investor and Public Relations 484-356-7105michael.parks@atossainc.com

Related News